Amedisys Inc (NASDAQ:AMED) Has Just Had Its Target Price Upgraded by Research Analysts at RBC Capital Markets to $41.00


Stock Analysis:Amedisys Inc (NASDAQ:AMED) Price Target Upgraded

In analysts note announced by RBC Capital Markets on Friday, 27 November, Amedisys Inc (NASDAQ:AMED) had its TP boosted to $41.00. The firm now has a solid “Sector Perform” rating on shares.

From a total of 4 analysts covering Amedisys Inc. (NASDAQ:AMED) stock, 1 rate it a ”Buy”, 0 a “Sell”, and 3 a ”Hold”. This means that 25% of the ratings are positive. The highest target price is $45 while the lowest target price is $41. The mean of all analyst targets is $43.67 with a 4.70% above today’s ($41.71) stock price. Amedisys Inc. was the topic of 4 analyst reports since September 1, 2015 according to the firm StockzIntelligence Inc. Mizuho downgraded shares on November 11 to “Neutral” rating.

The stock increased 1.51% or $0.62 on November 27, striking $41.71. Approximately 232,901 shares of stock traded hands. Amedisys Inc (NASDAQ:AMED) has risen 64.08% since April 27, 2015 and is uptrending. It has outperformed by 64.98% the S&P500.

Amedisys, Inc. is a health care at home company. The company has a market cap of $1.38 billion. Amedisys delivers home health and hospice care to more than 360,000 patients each year. It currently has negative earnings. The Firm has care network across 34 states.

According to Zacks Investment Research, “Amedisys, Inc. is a leading multi-regional provider of home health care nursing services. They operate home care nursing offices in southern and southeastern United States.” Get a free copy of the Zacks research report on Amedisys Inc (AMED)